A new report published in The New England Journal of Medicine (N Engl J Med January 2022) found that for adults who had previously received a full COVID-19 vaccine regimen of either Moderna, Pfizer, or Johnson & Johnson, an additional booster of any of these vaccines was safe and immunogenic. The study assessed adults who had been fully vaccinated with any of the three vaccines at least 12 weeks prior and who had no previous COVID-19 infection. A single booster was administered to each participant; depending on which initial vaccine the participant had received, the booster was either different than (heterologous) or the same as (homologous) the original vaccine. Participants reported side effects such as headache, pain at injection site, and muscle aches, but no serious adverse events. All combinations were found to increase neutralizing antibody levels, strongly suggesting that both heterologous and homologous COVID-19 booster combinations will...
Skip Nav Destination
Article navigation
Trends & Technology|
April 2022
Trends & Technology
ASA Monitor April 2022, Vol. 86, 22.
Citation
Trends & Technology. ASA Monitor 2022; 86:22 doi: https://doi.org/10.1097/01.ASM.0000826964.39558.6f
Download citation file:
Sign in
ASA members enjoy complimentary access to ASA publications, as well as a variety of educational resources. Join today!
Pay-Per-View Access
$20.00
Advertisement
151
Views
Email alerts
Related Articles
Trends & Technology
ASA Monitor (March 2022)
Trends & Technology
ASA Monitor (July 2021)
Trends & Technology
ASA Monitor (June 2022)
Trends & Technology
ASA Monitor (February 2021)
Trends & Technology
ASA Monitor (October 2021)
Advertisement